Top

Published in:

08-08-2023 | Hepatocellular Carcinoma | ASO Author Reflections

ASO Author Reflections: Association of Ferroptosis with Transferrin Receptor in Hepatocellular Carcinoma

Authors: Shinji Itoh, MD, PhD, Katsuya Toshida, MD, Maki Hiromatsu, Tomoharu Yoshizumi, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2023

Excerpt

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and its incidence has increased. Treatment of HCC, particularly hepatic resection, has improved during the past decades, but the rate of recurrence remains high.¹ Ferroptosis, a new type of cell death caused by lipid peroxidation in an iron-dependent manner, has received much attention in HCC.² Transferrin receptor protein (TFR) is known as a ferroptosis marker, but the detailed relationship between TFR expression and sensitivity to ferroptosis inducers, such as artesunate (AS), lenvatinib (LEN), and sorafenib (SOR), is not understood to date. …

Itoh S, Yoshizumi T, Yugawa K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020;72:1987–99. https://doi.org/10.1002/hep.31206.CrossRefPubMed

Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

Hiromatsu M, Toshida K, Itoh S, et al. Transferrin receptor is associated with sensitivity to ferroptosis inducers in hepatocellular carcinoma. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14053-7.CrossRefPubMed

Adachi M, Kai K, Yamaji K, et al. Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma. Histopathology. 2019;75:63–73. https://doi.org/10.1111/his.13847.CrossRefPubMed

Chen J, Ding C, Chen Y, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. Cancer Lett. 2021;502:154–65. https://doi.org/10.1016/j.canlet.2020.12.019.CrossRefPubMed

Title: ASO Author Reflections: Association of Ferroptosis with Transferrin Receptor in Hepatocellular Carcinoma
Authors: Shinji Itoh, MD, PhD
Katsuya Toshida, MD
Maki Hiromatsu
Tomoharu Yoshizumi, MD, PhD
Publication date: 08-08-2023
Publisher: Springer International Publishing
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Lenvatinib
Sorafenib
Published in: Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14054-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: Association of Ferroptosis with Transferrin Receptor in Hepatocellular Carcinoma

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2023

ASO Visual Abstract: Breast Cancer-Related Lymphedema (BCRL) and Bioimpedance Spectroscopy: Long-Term Follow-Up, Surveillance Recommendations, and Multidisciplinary Risk Factors

ASO Author Reflections: Association of Race/Ethnicity, Persistent Poverty, and Opioid Access Among Patients with Gastrointestinal Cancer Near the End of Life

ASO Author Reflections: Liver Resections with Vascular Reconstruction Using Veno-Venous Bypass and Cold Perfusion for Tumors with Venous Obstruction

ASO Author Reflections: Microsatellite Unstable Colon Cancer, Lymph Node Metastases, and Risk of Recurrence

Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy

Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms